1. Home
  2. SAR vs BCYC Comparison

SAR vs BCYC Comparison

Compare SAR & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saratoga Investment Corp New

SAR

Saratoga Investment Corp New

HOLD

Current Price

$21.38

Market Cap

372.7M

Sector

Finance

ML Signal

HOLD

Logo Bicycle Therapeutics plc

BCYC

Bicycle Therapeutics plc

HOLD

Current Price

$4.90

Market Cap

360.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAR
BCYC
Founded
2007
2009
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
372.7M
360.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SAR
BCYC
Price
$21.38
$4.90
Analyst Decision
Hold
Buy
Analyst Count
4
10
Target Price
$23.75
$14.00
AVG Volume (30 Days)
119.1K
538.4K
Earning Date
05-06-2026
04-30-2026
Dividend Yield
14.86%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.39
$37.20
P/E Ratio
$9.44
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.78
$4.24
52 Week High
$25.64
$9.55

Technical Indicators

Market Signals
Indicator
SAR
BCYC
Relative Strength Index (RSI) 39.61 50.08
Support Level N/A N/A
Resistance Level $23.41 $7.14
Average True Range (ATR) 0.61 0.32
MACD -0.07 0.04
Stochastic Oscillator 28.44 69.05

Price Performance

Historical Comparison
SAR
BCYC

About SAR Saratoga Investment Corp New

Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Share on Social Networks: